Cancer drug trial halted: REC-4881 fails to show promise in Gene-Mutated tumors

NCT ID NCT06005974

Terminated Disease control Sponsor: Recursion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily pill called REC-4881 in 18 adults aged 55+ with advanced solid tumors that had AXIN1 or APC gene mutations. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APC GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APC GENE MUTATION AXIN1 GENE MUTATION SOLID TUMOR

Contacts and locations

Locations

American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817, United States
Avera Cancer Institute

Sioux Falls, South Dakota, 57105, United States
Cancer Specialists of North Florida

Fleming Island, Florida, 32003, United States
Eastern Connecticut Hematology & Oncology Associates

Norwich, Connecticut, 06360, United States
Hunterdon Hematology Oncology

Hillsborough, New Jersey, 08844, United States
Mary Crowley Cancer Research Centers

Dallas, Texas, 75231, United States
Medical Oncology Hematology Consultants

Newark, Delaware, 19713, United States
Mission Cancer And Blood

Des Moines, Iowa, 50314, United States
Rocky Mountain Cancer Centers

Denver, Colorado, 80218, United States
Saint Luke's Hospital

Kansas City, Missouri, 64111, United States
Sansum Clinic

Santa Barbara, California, 93105, United States
Sharp Memorial Hospital

San Diego, California, 92123, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.